SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Vandenberghe R) srt2:(2020-2024)"

Sökning: WFRF:(Vandenberghe R) > (2020-2024)

  • Resultat 61-70 av 95
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  •  
62.
  •  
63.
  •  
64.
  •  
65.
  •  
66.
  •  
67.
  • Bader, I., et al. (författare)
  • Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study
  • 2023
  • Ingår i: Alzheimer's Research & Therapy. - 1758-9193. ; 15:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background The mismatch between the limited availability versus the high demand of participants who are in the pre-dementia phase of Alzheimer's disease (AD) is a bottleneck for clinical studies in AD. Nevertheless, potential enrollment barriers in the pre-dementia population are relatively under-reported. In a large European longitudinal biomarker study (the AMYPAD-PNHS), we investigated main enrollment barriers in individuals with no or mild symptoms recruited from research and clinical parent cohorts (PCs) of ongoing observational studies.Methods Logistic regression was used to predict study refusal based on sex, age, education, global cognition (MMSE), family history of dementia, and number of prior study visits. Study refusal rates and categorized enrollment barriers were compared between PCs using chi-squared tests.Results 535/1856 (28.8%) of the participants recruited from ongoing studies declined participation in the AMYPAD-PNHS. Only for participants recruited from clinical PCs (n = 243), a higher MMSE-score (beta = - 0.22, OR = 0.80, p < .05), more prior study visits (beta = - 0.93, OR = 0.40, p < .001), and positive family history of dementia (beta = 2.08, OR = 8.02, p < .01) resulted in lower odds on study refusal. General study burden was the main enrollment barrier (36.1%), followed by amyloid-PET related burden (PCresearch = 27.4%, PCclinical = 9.0%, X-2 = 10.56, p = .001), and loss of research interest (PCclinical = 46.3%, PCresearch = 16.5%, X-2 = 32.34, p < .001).Conclusions The enrollment rate for the AMYPAD-PNHS was relatively high, suggesting an advantage of recruitment via ongoing studies. In this observational cohort, study burden reduction and tailored strategies may potentially improve participant enrollment into trial readiness cohorts such as for phase-3 early anti-amyloid intervention trials. The AMYPAD-PNHS (EudraCT: 2018-002277-22) was approved by the ethical review board of the VU Medical Center (VUmc) as the Sponsor site and in every affiliated site.
  •  
68.
  • Collij, L. E., et al. (författare)
  • The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact
  • 2023
  • Ingår i: Frontiers in Neurology. - : Frontiers Media SA. - 1664-2295. ; 13
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundAmyloid-beta (A beta) accumulation is considered the earliest pathological change in Alzheimer's disease (AD). The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) consortium is a collaborative European framework across European Federation of Pharmaceutical Industries Associations (EFPIA), academic, and 'Small and Medium-sized enterprises' (SME) partners aiming to provide evidence on the clinical utility and cost-effectiveness of Positron Emission Tomography (PET) imaging in diagnostic work-up of AD and to support clinical trial design by developing optimal quantitative methodology in an early AD population. The AMYPAD studiesIn the Diagnostic and Patient Management Study (DPMS), 844 participants from eight centres across three clinical subgroups (245 subjective cognitive decline, 342 mild cognitive impairment, and 258 dementia) were included. The Prognostic and Natural History Study (PNHS) recruited pre-dementia subjects across 11 European parent cohorts (PCs). Approximately 1600 unique subjects with historical and prospective data were collected within this study. PET acquisition with [F-18]flutemetamol or [F-18]florbetaben radiotracers was performed and quantified using the Centiloid (CL) method. ResultsAMYPAD has significantly contributed to the AD field by furthering our understanding of amyloid deposition in the brain and the optimal methodology to measure this process. Main contributions so far include the validation of the dual-time window acquisition protocol to derive the fully quantitative non-displaceable binding potential (BPND), assess the value of this metric in the context of clinical trials, improve PET-sensitivity to emerging A beta burden and utilize its available regional information, establish the quantitative accuracy of the Centiloid method across tracers and support implementation of quantitative amyloid-PET measures in the clinical routine. Future stepsThe AMYPAD consortium has succeeded in recruiting and following a large number of prospective subjects and setting up a collaborative framework to integrate data across European PCs. Efforts are currently ongoing in collaboration with ARIDHIA and ADDI to harmonize, integrate, and curate all available clinical data from the PNHS PCs, which will become openly accessible to the wider scientific community.
  •  
69.
  •  
70.
  • Eap, C. B., et al. (författare)
  • Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests) : focus on antidepressants
  • 2021
  • Ingår i: World Journal of Biological Psychiatry. - : Taylor & Francis Group. - 1562-2975 .- 1814-1412. ; 22:8, s. 561-628
  • Forskningsöversikt (refereegranskat)abstract
    • Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient. Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic drug monitoring) and genotype relevant genetic polymorphisms of enzymes, transporters or receptors involved in drug metabolism or mechanism of action. Imaging studies, primarily positron emission tomography that relates drug concentrations in blood and radioligand binding, are considered to quantify target structure occupancy by the antidepressant drugs in vivo. Results: Evidence is given that in vivo imaging, therapeutic drug monitoring and genotyping and/or phenotyping of drug metabolising enzymes should be an integral part in the development of any new antidepressant drug. Conclusions: To guide antidepressant drug therapy in everyday practice, there are multiple indications such as uncertain adherence, polypharmacy, nonresponse and/or adverse reactions under therapeutically recommended doses, where therapeutic drug monitoring and cytochrome P450 genotyping and/or phenotyping should be applied as valid tools of precision medicine.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 61-70 av 95
Typ av publikation
tidskriftsartikel (92)
konferensbidrag (2)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (86)
övrigt vetenskapligt/konstnärligt (9)
Författare/redaktör
Vandenberghe, R (76)
Graff, C (64)
Sánchez-Valle, R (64)
Borroni, B. (63)
Galimberti, D (62)
Moreno, F (62)
visa fler...
de Mendonça, A (61)
Synofzik, M (59)
Masellis, M (58)
Otto, M. (58)
Ducharme, S (58)
Finger, E (58)
Santana, I (58)
Laforce, R (58)
Levin, J (56)
Rohrer, JD (56)
Gerhard, A (55)
Rowe, JB (54)
Sorbi, S (52)
van Swieten, JC (48)
Tartaglia, MC (45)
Butler, CR (43)
Bocchetta, M (40)
Pasquier, F (36)
Tagliavini, F (35)
Seelaar, H (35)
Le Ber, I (31)
Cash, DM (29)
Convery, RS (28)
Russell, LL (26)
Jiskoot, LC (25)
Zetterberg, Henrik, ... (21)
Bouzigues, A (20)
Tiraboschi, P (18)
Jiskoot, L (17)
Blennow, Kaj, 1958 (16)
Scheltens, P (16)
Ghidoni, R (15)
Frisoni, G (15)
Heller, C. (14)
Popp, J (14)
Vandenberghe, Rik (13)
Tsolaki, M (13)
Archetti, S (13)
Lleó, A. (12)
Butler, C. (12)
Premi, E. (12)
Benussi, A. (12)
van Swieten, J (12)
Tartaglia, C (12)
visa färre...
Lärosäte
Karolinska Institutet (92)
Göteborgs universitet (24)
Örebro universitet (9)
Kungliga Tekniska Högskolan (4)
Uppsala universitet (4)
Linköpings universitet (4)
visa fler...
Lunds universitet (4)
Stockholms universitet (3)
Umeå universitet (2)
Högskolan i Halmstad (2)
Jönköping University (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (95)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (36)
Naturvetenskap (3)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy